Mark E. Laughlin, Kevin Chatham-Stephens, Aimee L. Geissler
Infection is caused by gram-negative, spiral-shaped microaerophilic bacteria of the family Campylobacteraceae. Most infections are caused by Campylobacter jejuni; at least 18 other species, including C. coli, also cause infection. C. jejuni and C. coli are carried normally in the intestinal tracts of many domestic and wild animals.
The major modes of transmission include eating contaminated foods (especially undercooked chicken and foods contaminated by raw chicken), drinking contaminated water or milk (unpasteurized milk, most commonly), and having contact with animals, particularly farm animals such as cows and chickens, as well as domestic cats and dogs. Campylobacter can also be transmitted from person to person by the fecal–oral route.
Campylobacter is a leading cause of bacterial diarrheal disease worldwide and caused 96 million cases in 2010; in the United States, it is estimated to cause 1.3 million human illnesses every year. The risk of infection is highest in travelers to Africa and South America, especially to areas with poor restaurant hygiene and inadequate sanitation. The infectious dose is small; <500 organisms can cause disease.
Incubation period is typically 2–4 days but can range from 1 to 10 days. Campylobacteriosis is characterized by diarrhea (frequently bloody), abdominal pain, fever, and occasionally nausea and vomiting. More severe illness can occur, including dehydration, bloodstream infection, and symptoms mimicking acute appendicitis or ulcerative colitis. People with campylobacteriosis are at increased risk for postinfectious complications, including reactive arthritis (2%–5% of patients), irritable bowel syndrome (9%–13%), and Guillain-Barré syndrome (GBS) (0.1%). C.jejuni is the most frequently observed antecedent bacterial infection in cases of GBS; symptoms usually begin 1–3 weeks after the onset of Campylobacter enteritis.
Diagnosis is traditionally based on isolation of the organism from stool specimens or rectal swabs by using selective media incubated under reduced oxygen tension at 42°C (107.6°F) for 72 hours. A stool specimen should be collected as early after symptom onset as possible and before antibiotic treatment is initiated. Because the organism is fastidious, a delay in transporting the specimen to the laboratory will affect the viability of Campylobacter spp. A laboratory may reject stool samples without preservative that are in transit for more than 2 hours. If transport and processing are not possible within 2 hours of stool sample collection, specimens should be placed in transport medium according to standard guidelines. Only through culture can Campylobacter be subtyped and tested for antimicrobial susceptibility. Rapid culture-independent diagnostic tests, including both antigen tests and nucleic acid–based tests, are becoming widely available and more commonly used. The sensitivity and specificity of stool antigen tests are variable, and in settings of low prevalence, the positive predictive value is likely to be low. Therefore, laboratories should confirm positive results of stool antigen tests by culture. Nucleic acid–based tests have recently been approved and appear to have higher sensitivity and specificity than the antigen tests. Campylobacteriosis is a nationally notifiable disease.
The disease is generally self-limited, lasting a week or less. Antibiotic therapy decreases the duration of symptoms and bacterial shedding if administered early in the course of disease. Because campylobacteriosis generally cannot be distinguished from other causes of travelers’ diarrhea without a diagnostic test, the use of empiric antibiotics in travelers should follow the guidelines for travelers’ diarrhea.
Rates of antibiotic resistance, especially fluoroquinolone resistance, have risen sharply in the past 20 years, and high rates of resistance are now seen in many regions. Travel abroad is a risk factor for infection with resistant Campylobacter. Clinicians should suspect resistant infection in returning travelers with campylobacteriosis in whom empiric fluoroquinolone treatment has failed. When fluoroquinolone resistance is proven or suspected, azithromycin is usually the next choice of treatment, although resistance to macrolides has also been reported.
No vaccine is available. Prevention is best achieved by adhering to standard food and water safety precautions (see Chapter 2, Food & Water Precautions) and thorough handwashing after contact with animals or environments that may be contaminated with animal feces. Antibiotic prophylaxis is not recommended.
Fitzgerald C, Nachamkin I. Campylobacter and Arcobacter. In: Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, et al., editors. Manual of Clinical Microbiology. 11th ed. Washington, D.C.: American Society for Microbiology Press; 2015. pp. 998–1012.
Geissler AL, Bustos Carrillo F, Swanson K, Patrick ME, Fullerton KE, Bennett C, et al. Increasing Campylobacter infections, outbreaks, and antimicrobial resistance in the United States, 2004–2012. Clin Infect Dis. 2017 Jul:65(10):1624–31.
Humphrey T, O’Brien S, Madsen M. Campylobacters as zoonotic pathogens: a food production perspective. Int J Food Microbiol. 2007 Jul 15;117(3):237–57.
Kaakoush NO, Castaño-Rodríguiz N, Mitchell HA, Man SM. Global epidemiology of Campylobacter infection. Clin Microbiol Rev. 2015 July;28(3):687–720.
Kendall ME, Crim S, Fullerton K, Han PV, Cronquist AB, Shiferaw B, et al. Travel-associated enteric infections diagnosed after return to the United States, Foodborne Diseases Active Surveillance Network (FoodNet), 2004–2009. Clin Infect Dis. 2012 Jun;54 Suppl 5:S480–7.
Tribble DR. Resistant pathogens as causes of traveller’s diarrhea globally and impact(s) on treatment failure and recommendations. J. Travel Med. 2017 Apr 1;24(Suppl 1):S6–12.